Introduction Sagent Pharmaceuticals is a privately-owned specialty pharmaceutical firm that concentrates on the development, production, sourcing, and marketing of pharmaceutical goods, with a particular emphasis on injectable medications. The company has established a distinct global network of resources, which includes quick development capabilities, sophisticated manufacturing techniques, and cutting-edge drug delivery technologies. This has resulted in an extensive portfolio of pharmaceutical products that meet the changing needs of patients. |
Disease Domain | Count |
---|---|
Infectious Diseases | 2 |
Nervous System Diseases | 1 |
Hemic and Lymphatic Diseases | 1 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Synthetic peptide | 1 |
Monoclonal antibody | 1 |
Top 5 Target | Count |
---|---|
SARS-CoV-2 S protein | 1 |
DRDs(Dopamine receptors) | 1 |
Target- |
Mechanism Cell membrane function inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date12 Sep 2003 |
Target |
Mechanism DRDs agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date24 Oct 1964 |
Target |
Mechanism SARS-CoV-2 S protein inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2/3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date09 Nov 2020 |
Sponsor / Collaborator |
Start Date19 Aug 2020 |
Sponsor / Collaborator |
Start Date01 Apr 2015 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Daptomycin | Complicated skin and skin structure infection More | Approved |
BMS-986414 ( SARS-CoV-2 S protein ) | COVID-19 More | Phase 2/3 |